The objective of the present studies was to examine the interaction between brain-derived angiotensin II (Ang II) and prostaglandins in order to identify the mechanisms mediating the pressor response produced by these neuroregulators. Inhibiting synthesis of prostaglandins with indomethacin [indocin, 200 µg/ 5 µl artificial cerebrospinal fluid (aCSF)], administered intracerebroventricularly (icv) to conscious adult male Sprague-Dawley rats, reduced blood pressure to values below basal levels. When injected prior to Ang II (50 ng/5 µl aCSF; icv), indomethacin completely abolished the pressor response induced by the octapeptide. The increase in blood pressure produced by prostaglandin D 2 (PGD 2 , 20 µg/5 µl; icv), the most prominent prostaglandin in the rat brain, however, was not prevented by losartan (25 µg/5 µl; icv), an Ang II AT 1 -receptor antagonist. Collectively, these results indicate that prostaglandins produced tonically in the brain maintain resting arterial blood pressure and that the pressor action of Ang II is dependent on de novo synthesis of a prostaglandin.
Introduction
We have previously shown 1 in conscious rats that decreasing central production of nitric oxide (NO) via icv administration of N G -nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase (NOS), produces a biphasic pressor response: an initial, transient increase within five minutes, followed by a long-lasting pressor response at 60-90 minutes. The initial, but not the delayed, increase in blood pressure is abolished by pretreatment with either icv losartan, an Ang II AT 1 -receptor antagonist (AIIA), or indomethacin, an inhibitor of cyclo-oxygenase. These results indicate that NO produced within the brain maintains resting arterial blood pressure partially through modulation of the brain angiotensin and prostaglandin systems.
Several studies indicate that, in the periphery, prostaglandins stimulate the renin-angiotensinaldosterone system (RAAS), [2] [3] [4] [5] while the central effect of Ang II on blood pressure requires a product of cyclo-oxygenase, presumably prostaglandins. 6 Because of these known interactions, the present studies were designed to determine whether the pressor effect of prostaglandin D 2 (PGD 2 ) is mediated by Ang II, or whether the elevation in blood pressure caused by Ang II requires activation of cyclo-oxygenase. PGD 2 was chosen for these stud-ies because it is the primary prostaglandin present in the rat brain. 7
Materials and methods Animals
Adult male, Sprague-Dawley rats, weighing between 210-296 g, were housed, three per cage, in a temperature (22°C) and humidity-controlled environment, with a 12-hour light cycle (lights on 0600 hours). Food and water were available ad libitum. The animals were allowed to adapt to the environment for at least three days before surgery.
Surgery
Rats (n=84) were anaesthetised with a combination of ketamine (60 mg/kg, i.m.) and nembutal (40 mg/kg, i.p.). A 20-gauge stainless steel guide cannula, sealed with silicone to prevent leakage of cerebrospinal fluid (CSF), was stereotactically implanted into the right cerebroventricle, on a flat skull, at the following coordinates: 0.8 mm posterior to bregma, 1.2 mm lateral to the midline and 3.5 mm below the surface of the dura. The cannula was secured to the skull with two jeweller's screws and dental cement. The animals were placed in individual cages after surgery and were handled daily to condition them to the investigators and minimise the effects of stress during the experiment.
Seven to ten days after implantation of the icv cannula, the rats were deprived of water for approximately 24 hours. This was done to optimise the role of the brain RAAS. On the day of the experiment, animals were anaesthetised with halothane (1.5% in oxygen) and one femoral artery was catheterised with PE-50 tubing for recording of arterial blood pressure. The catheter was filled with heparinised saline (100 units/ml), tunnelled under the skin, and exteriorised and secured at the nape of the neck. The rats were allowed to regain consciousness and experiments were performed at least two hours later, between 1400 and 1500 hours.
Measurement of physiological variables in blood
An arterial blood sample (~750 µl) was collected for measurement of basal haematocrit, plasma protein concentration, osmolality and [Na + ] and [K + ]. Haematocrit was measured in microcapillary tubes. Plasma protein concentration was determined with a hand held refractometer (Schuco, Japan). Plasma osmolality was quantified with a vapour pressure osmometer (model 5500,Wescor, Logan, UT) and [Na + ] and [K + ] were determined with a flame photometer (model IL943, Instrumentation Labs, Lexington, MA).
Measurement of blood pressure
Mean arterial blood pressure (MABP) was recorded from the arterial catheter by means of a pressure transducer (Model TXD-310) attached to a Micro-Med digital blood pressure monitor (Model Digi-Med BPA-190b, Louisville, KY) and a PC-based data acquisition and processing system (Model DMSI-200, Louisville, KY).
Data were processed and stored every five minutes for the duration of the experiment. A 30gauge stainless steel injector, which extended 0.5 mm below the tip of the icv guide cannula, was introduced and left in place for five minutes before an injection of 5 µl of the vehicle, aCSF (or normal saline) or drug was given. The composition of the aCSF was 3. 35 Two studies were conducted according to the following protocols:
Study 1 Effect of losartan (icv) on the pressor effect of PGD 2 (icv)
Rats were assigned randomly to four groups. After obtaining a stable 30-minute recording of basal MABP, animals (n=8-11 per group) received two icv injections, 10 minutes apart.Vehicle (aCSF, 5 µl) or losartan (25 µg/5 µl), a non-peptide AIIA without agonist properties, was injected initially, followed by PGD 2 (20 µg/5 µl) or vehicle, (10% ethanol in aCSF, 5 µl). MABP was recorded continuously for the following 120 minutes.
Study 2 Effect of indomethacin (icv) on the pressor effect of Ang II (icv)
Rats were assigned randomly to four groups (n=12 each). After obtaining a stable 30 minute recording of basal blood pressure normal saline (5 µl), or indomethacin (200 µg/5 µl) was given icv 10 minutes prior to icv administration of ANG II (50 ng/5 µl) or aCSF (5 µl). MABP was recorded continuously for the following 120 minutes.
Statistical analysis
Blood pressure Changes in MABP relative to time zero were analysed using a two-factor analysis of variance with repeated measures on time. The two factors were: treatment group (aCSF/vehicle, aCSF/PGD 2 , losartan/vehicle and losartan/PGD 2 in Study 1, and normal saline/ aCSF, normal saline/Ang II, indomethacin/aCSF and indomethacin/Ang II in Study 2), and time (12 time points,from -10 minutes to 120 minutes). The analysis of variance was followed by the Fisher's least significant difference procedure for multiple comparisons, with the Bonferroni adjustment for the number of comparisons. All tests were assessed at the 0.05 level of significance.
Other physiological variables
Mean values of haematocrit, plasma protein concentration, osmolality and [Na + ], and [K + ] were compared between groups using a one-way analysis of variance.
Results

Study 1. Effect of losartan (icv) on the pressor effect of PGD 2 (icv) Measurement of physiological variables in blood
The mean values of haematocrit, plasma protein concentration, osmolality, [Na + ] and [K + ] did not differ significantly between rats in the four treatment groups (Table 1) , indicating similar basal physiological conditions.
Blood pressure
The means of basal MABP prior to icv injections were similar in the four groups of rats (mmHg, means ± SEM, n=8-11; aCSF/vehicle, 115±3; losartan/vehicle, 119±3; aCSF/PGD 2 119±3; and losartan/PGD 2 , 117±3). Administration of aCSF/vehicle and aCSF/losartan (icv) did not significantly change MABP during the 120 minutes experimental period (Figure 1 ). After 60 minutes, blood pressure tended to decline slightly during sleeping in all animals. Icv injection of PGD 2 following vehicle produced an increase in MABP (p<0.05), which reached a peak at 30 minutes and declined gradually thereafter, returning to basal levels by the end of the experiment. Pretreatment with losartan did not significantly modify the pressor response to PGD 2 (Figure 1 ).
Study 2. Effect of indomethacin (icv) on the pressor effect of ANG II (icv) Measurement of physiological variables in blood
The mean values of haematocrit, plasma protein concentration, osmolality, [Na + ] and [K + ] were similar among rats assigned randomly to the four different groups prior to administration of vehicle, or indomethacin, icv ( Table 2 ).
Blood pressure
The mean basal values of blood pressure before PAPER the icv injections were similar among rats assigned randomly to the four different treatment groups of the study (mmHg, means ± SEM, n=12 each; normal saline/aCSF, 121±3; normal saline/Ang II, 122±2; INDO/aCSF, 126±2; and INDO/Ang II 127±2). MABP did not change during the first 90 minutes after icv administration of normal saline/aCSF (p>0.05), but decreased gradually, reaching significantly lower values (p<0.05) at 105 and 120 minutes (Figure 2) , coinciding with the animals' sleeping behaviour. Administration of Ang II after normal saline icv rapidly increased arterial blood pressure, which reached a peak at 10 minutes and then declined slowly to basal levels. Indomethacin treatment followed by aCSF icv progressively decreased blood pressure, which reached levels significantly lower than baseline by 15 minutes (p<0.05) and remained low until the end of the experiment at 120 minutes. When injected prior to Ang II, indomethacin prevented the peptide-induced pressor response and produced a decline in blood pressure similar to that observed after administration with aCSF ( Figure 2 ).
Discussion
The results of our experiments suggest that prostaglandins are continually synthesised via cyclo-oxygenase within the brain to maintain resting arterial blood pressure, in as much as a progressive decrease in blood pressure was observed following icv administration of indomethacin.This is a novel finding since in earlier studies reported by Inoue et al. 8 a delayed decrease in resting arterial blood pressure after treatment with meclofenamate, another inhibitor of cyclo-oxygenase, was not observed. In their experiments, however, the recording period did not extend beyond 15 minutes, a time when significant decreases had only begun to occur in response to indomethacin in our studies. Additionally, our studies show that the pressor effect of Ang II administered icv depends upon the synthesis of a prostaglandin since the Ang II-induced pressor response is prevented by pretreatment with indomethacin. Similarly, Inoue et al. 8 reported that administration of meclofenamate icv attenuated the initial peak pressor response that occurred at two minutes after Ang II Values are means ± SEM for the number of animals indicated.
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icv, but that the sustained pressor response at five and 15 minutes was completely abolished by the drug treatment. Conversely, the elevation of blood pressure produced by PGD 2 is independent of Ang II, since losartan icv, the Ang II AT 1 -receptor antagonist devoid of agonist properties, did not inhibit the pressor response elicited by this prostaglandin. The dose of losartan used was effective in blocking the elevation in blood pressure elicited by Ang II (50 ng) icv for up to 120 minutes. Inoue et al. 8 also demonstrated that saralasin, an Ang II receptor antagonist with agonist properties, was unable to prevent the pressor response to PGD 2 . Additionally, our studies demonstrate that Ang II is not produced tonically within the brain to maintain resting arterial blood pressure, since AT 1receptor blockade using losartan did not alter basal MABP.
A functional interaction between Ang II and prostaglandins was suspected in our previous studies 1 by the finding that the immediate increase in blood pressure induced by inhibition of the central production of NO with L-NAME icv was abolished by either losartan or indomethacin, given icv. The short-term control of resting arterial blood pressure by centrally-produced NO thus appears to operate partially by inhibiting the action of an angiotensinergic pathway that, in turn, activates cyclo-oxygenase and synthesis of prostaglandin(s) required for the pressor response. Alternatively, a prostaglandin could stimulate the synthesis of Ang II. A positive feedback mechanism by which prostaglandins stimulate the RAAS 9 and Ang II enhances the synthesis of prostaglandins [9] [10] [11] has been demonstrated in peripheral tissues. It is possible, therefore, that a similar interaction exists in the central nervous system.
The presence of prostaglandins in the brain was recognised more than 30 years ago and rapidly confirmed by other investigators. 12 Their production is catalysed by several direct and indirect enzymatic pathways that produce arachidonic acid. 13 The direct pathway involves activation of phospholipase A 2 , phospholipid breakdown and Table 2 Physiological values prior to icv injection of drugs in animals deprived of water for 24 hours and assigned randomly to the four treatment groups. release of fatty acids, including arachidonic acid, which is converted to prostaglandins by cyclooxygenase. The indirect pathways require activation of phospholipase C, followed by diacylglycerol and monoacylglycerol lipases to produce arachidonic acid. Ang II stimulates production of prostaglandins via similar direct and indirect biochemical cascades by interaction with AT 2 -and AT 1 -receptor subtypes. 10, 13 Importantly, production of the three major prostaglandins PGD 2 , PGE 2 , PGF 2α and the two stable metabolites of prostacyclin PGI 2 (6-keto-PGF 1α and PGF 1α ) and of thromboxane A 2 (thromboxane B 2 ) has been demonstrated in vitro by incubation of homogenates of brain, pituitary and pineal gland from the rat. 14 The distribution of these various prostaglandins is varied, with marked heterogeneity within anatomically and functionally defined areas of the brain, suggesting specific, but differing, physiologic roles. Accordingly, it has been shown that prostaglandins regulate numerous functions, such as sleep, body temperature, 15 hormone secretion, 16 pain sensation, 17 food intake, 18 and modulation of release of neurotransmitters and neuropeptides. 19 For example, prostaglandins can inhibit norepinephrine release from nerve terminals 19 and the action of norepinephrine on brain neurons, 20 as well as attenuate acetylcholinesterase activity in the hypothalamus. 21 Iontophoresis of PGE 2 or PGF 2 enhances electrical firing rates of neurons in specific brain areas. 22 Moreover, emerging evidence indicates that, in the brain, prostaglandins contribute to the regulation of blood pressure homeostasis.
Our results, as well as those of others, demonstrate that prostaglandins, administered centrally, increase arterial blood pressure. 7, 8, 23, 24 Conversely, inhibiting the synthesis of prostaglandins with indomethacin produces a greater fall in MABP during haemorrhage, 25 emphasising the importance of these biologically active lipids in the compensatory regulation of blood pressure during hypotension. Although, in the periphery, prostaglandins stimulate the RAAS, 9 the results of our experiments indicate that the central effects of PGD 2 on blood pressure do not depend on Ang II interaction at AT 1 -receptors, since losartan was ineffective in altering the pressor response elicited by this neurochemical modulator. In contrast, the pressor effect of Ang II does depend on the synthesis of prostaglandin.
Importantly, several components of the RAAS, i.e., renin, angiotensinogen, angiotensin-converting enzyme and Ang II have been identified in the brain, [26] [27] [28] [29] particularly in brain regions recognised to regulate blood pressure. 10, 30 Specifically, there is an abundance of Ang II receptors, especially of the AT 1 subtype, expressed throughout structures of the lamina terminalis in the forebrain. 10, [31] [32] [33] [34] Recently, a transgenic rat model was created by insertion of the mouse Ren-2 renin gene in their genome, which resulted in over-expression of brain renin and development of severe hypertension. 35 Moreover, in this rat model of hyperten-sion, concentrations of Ang II are elevated in the hypothalamus and in the medulla oblongata, 36 providing further evidence that this centrally produced neuropeptide is an important neuroregulator of blood pressure. Interactions of Ang II and prostaglandins in the central nervous system are less well documented. To the best of our knowledge, changes in prostaglandin in response to Ang II have not been measured in specific areas of the brain, particularly in the lamina terminalis, although Ang II has been shown to increase prostaglandin levels in the CSF. 37 Future studies on these interactions should clarify the neurobiology of Ang II actions within forebrain and hindbrain networks involved in the regulation of cardiovascular function.
